REMSleep secures coding approval for DeltaWave
By HME News Staff
Updated 8:47 AM CST, Mon February 2, 2026
BLACKSHEAR, Ga. - REMSleep Holdings has announced that it has received HCPCS approval from the Pricing, Data Analysis and Coding (PDAC) contractor for its DeltaWave nasal pillow system. This approval allows durable medical equipment (DME) providers to bill Medicare and private insurance payers for all configurations of the DeltaWave system. “This marks a critical milestone for our DME partners who now have everything they need, the expanded FDA clearance, HCPCS codes for all configurations, and a fully stocked inventory,” said Thomas Wood, CEO and founder of REMSleep. “We are excited to proceed with the full commercial launch of DeltaWave, offering a solution that meets the diverse needs of the sleep therapy market.” Earlier this month, REMSleep announced expanded 510(k) clearance from the U.S. Food and Drug Administration, significantly broadening DeltaWave’s indicated use beyond home-based CPAP therapy to include institutional settings and a wider range of patient populations. With regulatory and reimbursement barriers now cleared, the company is activating a three-channel strategy that includes reaching out to DME providers to target the 20% to 30% of CPAP patients who fail their initial mask. “We have transitioned from a soft launch with a limited FDA clearance to being fully prepared for national distribution,” Wood said. “This is a significant leap toward providing a complete solution for our customers.”
Comments